Rani Therapeutics Holdings, Inc. Class A Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RANI, updated each market day.
RANI AI Sentiment
AI sees no strong directional signal for Rani Therapeutics Holdings, Inc. Class A Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Rani Therapeutics Holdings, Inc. Class A Common Stock
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Sector
Exchange
Market Cap
$77,783,103
Cap Tier
Employees
69
Headquarters
SAN JOSE, CA
Listed Since
July 30, 2021
Website
RANI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RANI Volatility
Rani Therapeutics Holdings, Inc. Class A Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
